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Abstract 
Purpose: To design controlled release ketorolac tromethamol (KT) matrix tablets for increased drug 
bioavailability.  
Methods: Waxes (Compritol® ATO 888, Precirol® ATO 5 and stearic acid - SA) and polymers 
(hydroxypropyl methylcellulose - HPMC and xanthan gum - XG) were used in the preparation of the 
matrix tablets at various excipient concentrations for controlled drug delivery. The physical properties of 
the formulations were determined. Drug release profiles from the tablets were obtained and their drug 
release mechanisms were characterized by kinetic modeling. Analytical quantification method of KT in 
dissolution media was also validated by certain performance criteria.  
Results: KT matrix tablets prepared individually with Compritol and HPMC at 30 and 40 % 
concentrations, respectively, displayed the best tablet compression properties. The tablets prepared 
with HPMC and XG displayed slower drug release profiles compared to the tablets prepared with waxes 
in general (p < 0.05). KT release increased with increase in pH since it is a weak acid (p < 0.05). 
Statistically insignificant difference was observed among all the tablets prepared with HPMC and XG in 
water (p > 0.05). However, drug release from the tablets containing 40 % XG was faster than tablets 
prepared with HPMC (30  and 40 %) and XG (30 %) at pH 7.2 (p < 0.05). Drug release mechanisms 
from the tablets prepared with wax and polymers were non-Fickian, indicating coupled diffusion/erosion 
and diffusion/polymer relaxation, respectively.   
Conclusion: KT matrix tablets have been successfully formulated by direct compression method. The 
findings demonstrate that both the desired physical characteristics and drug release profiles were 
obtained for matrix tablets prepared with HPMC. 
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Ketorolac tromethamol (KT) [(±) - 5-benzoyl - 2, 3 
- dihydro - 1H – pyrrolizine - 1 -carboxylic acid 
compound with 2 - amino - 2 - (hydroxymethyl) - 
1, 3 – propanediol (1:1)] is a non-steroidal anti-
inflammatory drug (NSAID) of heterocyclic acetic 
acid derivatives which has a pKa of 3.54 [1,2]. It 
is used for short-term management of 
moderately severe acute and/or postoperative 
pain to reduce postoperative narcotic 
requirements. It is rapidly and completely 
absorbed in gastrointestinal tract. Its terminal 
half-life has been reported to be in the range of 
5.5 h for healthy subjects. Peak plasma 
concentration occurs averagely 35 min after 
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administration of single dose. Its recommended 
initial dose is 10 mg followed by 10 - 30 mg every 
4 - 6 h. It is prescribed for not more than 5 days 
for adults and as a single dose for children. 
Because of the risk of possible serious side 
effects, it is not suitable for long-term therapy 
[3,4] related to gastrointestinal system 
(ulceration, bleeding and/or perforation of the 
stomach or intestines), vascular (cerebrovascular 
bleeding) and cardiovascular systems 
(cardiovascular thrombosis, myocardial infarction 
and stroke), urinary system (renal impairment).  
 
The undesirable side effects of KT can be 
minimized if it is introduced in a dosage form that 
provides controlled drug delivery after oral 
administration. Matrix tablets are suitable dosage 
forms in this regard. When they provide 
sustained drug release in the gastrointestinal 
track, risk of systemic side effects of drugs can 
be minimized by administering lower daily dose 
to the patients. Matrix tablets also relatively easy 
and cost-effective to produce with high 
reproducibility, unlike conventional tablets for 
rapid drug release [5,6].  
 
The aim of this study was to design matrix tablets 
of KT for sustained drug release. Thus, 
maintaining drug in the systemic circulation for a 
longer time period, using a low dose may 
decrease the risk of side effects of KT, thus 






Ketorolac tromethamol was provided from Dr. 
Reddy’s Laboratories Ltd. in India. Precirol® 
ATO 5 and Compritol® 888 ATO were obtained 
from Gattefossé in France. Stearic acid, xanthan 
gum and polyvinylpyrollidone K-90 were 
purchased from Cognis (Germany), CP Kelco 
(USA) and BASF (Germany), respectively. 
Methocel® K15 Premium EP was kindly provided 
from Colorcon (England). Avicel® PH-102 and 
magnesium stearate were obtained from Select-
chemie AG (Switzerland) and Prever (Italy), 
respectively. 
  
Preparation of matrix tablets  
 
Placebo and KT tablets were prepared by direct 
compression method. KT tablets were formulated 
containing 40 mg KT in 180 mg total tablet 
weight (Table 1). Tablets were compressed by 
using a biconvex punch 8.0 mm in diameter on a 
single punch tabletting machine (Korsch EK/O, 
Germany) under 6895 kp compression force. 
 
Physical characterization of matrix tablets 
 
Carr’s indexes (CI) and Hausner ratios (HR) of 
powder mixtures were determined before 
compression of placebo and KT matrix tablets 
[7,8]. 
 















PCo-30 - 63.20 30 - - - - 5 0.8 1 
PCo-40 - 53.20 40 - - - - 5 0.8 1 
PPr-30 - 63.20 - 30 - - - 5 0.8 1 
PPr-40 - 53.20 - 40 - - - 5 0.8 1 
PSA-30 - 63.20 - - 30 - - 5 0.8 1 
PSA-40 - 53.20 - - 40 - - 5 0.8 1 
PHPMC-30 - 63.20 - - - 30 - 5 0.8 1 
PHPMC-40 - 53.20 - - - 40 - 5 0.8 1 
PXG-30 - 63.20 - - - - 30 5 0.8 1 






Co-30 22.22 40.98 30 - - - - 5 0.8 1 
Co-40 22.22 30.98 40 - - - - 5 0.8 1 
Pr-30 22.22 40.98 - 30 - - - 5 0.8 1 
Pr-40 22.22 30.98 - 40 - - - 5 0.8 1 
SA-30 22.22 40.98 - - 30 - - 5 0.8 1 
SA-40 22.22 30.98 - - 40 - - 5 0.8 1 
HPMC-30 22.22 40.98 - - - 30 - 5 0.8 1 
HPMC-40 22.22 30.98 - - - 40 - 5 0.8 1 
XG-30 22.22 40.98 - - - - 30 5 0.8 1 
XG-40 22.22 30.98 - - - - 40 5 0.8 1 
Note: Each formulation also contained PVP K90 (5 %), Aerosil (0.8 %) and magnesium stearate (1 %) 
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Bulk volume of 10 g of powder in a 25 mL 
measuring cylinder was recorded and the powder 
was then tapped 1250 times in a packed density 
apparatus (Erweka SVM 202, Germany) to 
determine packed volume. CI and HR were 
calculated via bulk and packed densities [9]. 
 
Physical characterization of tablets was tested in 
order to determine weight variation, tablet 
diameter and thickness, hardness, percent 
friability, disintegration time [10,11]. Variations in 
tablet weights were determined on 20 tablets 
using a balance (Denver Instrument). Friability 
was determined by using 20 tablets in an Erweka 
TAR 220 friability tester (Germany) for 4 min at 
25 rpm. Disintegration time of 6 tablets of each 
formulation was determined using an Erweka ZT 
320 disintegrator (Germany) according to USP 
32. Diameter, thickness and hardness of 10 
tablets of each formulation was tested with an 
Erweka TBH 525 hardness tester (Germany). 
Tensile strength was obtained from the fracture 
of tablets by diametral compression [10,12]. 
 
Validation of analytical method for 
quantification of ketorolac tromethamol 
 
The analytical method for quantification of KT in 
distilled water, pH 1.2 (HCl) and pH 7.2 
phosphate buffer (PB) solutions was validated 
and verified for linearity, intra-day and inter-day 
precision, accuracy, recovery and specifity by UV 
spectroscopy (Shimadzu UV-1700 
Spectrophotometer, Japan). Each study was 
replicated 6 times [13].  
 
To achieve this, UV spectra of KT were taken at 
each dissolution medium by scanning samples 
from 180 nm to 400 nm wave lengths at the 
absorbance mode of the apparatus. Absorption 
spectra of KT showed λmax at 323 nm at each of 




The linearity of the method was evaluated by 
standard linear regression analysis. 2, 4, 6, 8, 10 
and 12 µg/mL standard KT solutions in 
dissolution media were prepared by proper 
dilutions of 1000 µg/mL stock KT solutions. 
Absorbance of standard solutions was measured 
at 323 nm in distilled water, pH 1.2 (HCl) and pH 
7.2 (PB) solutions. Calibration curves were 
constructed by plotting concentration versus 
absorbance using linear regression analysis. 
 
Precision, accuracy and recovery  
 
Intra-day and inter-day precision and the 
accuracy of the method were calculated from 
data obtained during a 2-day validation. The 
precision of the method was determined by intra-
day repeatability and inter-day intermediate 
precision. KT solutions in dissolution medium (2, 
4, 6, 8, 10 and 12 µg/mL) were prepared by 
proper dilutions of the stock KT solution (1000 
µg/mL) six times on the same day. Intermediate 
precision was assessed by comparing the 





Precision was expressed as the relative standard 
deviation (RSD, %). Accuracy was expressed as 
the mean relative error (MRE, %). Recovery (%) 





The specificity of the method was investigated for 
demonstrating that the constituent in the 
formulations did not interfere quantification of KT. 
For this purpose, placebo tablets were crushed 
and then powdered in a mortar. 0.5 g powder 
was weighed into a 250 mL volumetric flask. 100 
mL medium was added and the mixture was 
homogenized in an ultrasonic bath for 15 min. 
The mixture was diluted to 250 mL with 
additional medium. 0.2 mL supernatant was 
withdrawn, diluted to 10 mL with the medium and 
assayed at 323 nm. This study was repeated for 
each tablet series in three dissolution media.   
 
Determination of content uniformity of matrix 
tablets 
 
Tablets were powdered in a mortar. Powder 
containing KT equivalent to 40 mg were taken 
into a 100 mL volumetric flask and diluted with 50 
mL water. The suspension was kept in an 
ultrasonic bath for 5 min. The suspension was 
filtered through a S & S5893 blue ribbon filter 
paper (Schleicher und Schuell, Germany) after 
being diluted to 100 mL with additional medium. 
Supernatant (2 mL) was withdrawn and diluted 
properly. The final solution was assayed by UV 
spectroscopy. Each study was replicated 6 times. 
Thus, percent of KT content to the target content 
(40 mg) per dosage unit was calculated to 
determine content uniformity according to The 
United States Pharmacopoeia 28 and National 
Formulary 23 (USP 28-NF 23) [14]. 
 
In vitro drug release studies 
 
The release of KT from tablets was studied 
according to the USP 32 Type II (paddle method) 
at 37 ± 0.5 oC in 900 mL distilled water, pH 1.2 
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(HCl) and pH 7.2 (PB) solutions at 50 rpm 
rotation speed by using a Varian dissolution 
apparatus (U.S.A.). One milliliter samples were 
taken by autosampling unit at predetermined 
time intervals and diluted to 10 mL and filtered 
through the S&S5893 type blue ribbon filter 
paper. Solutions were assayed by UV 
spectroscopy at 323 nm. 
 
The kinetics of drug release from matrix tablets in 
three dissolution media were evaluated by zero-
order, first-order and Higuchi root-square models 
[9,15]. The dissolution data were also evaluated 
according to Korsmeyer-Peppas equation 
(exponential equation) since these models fail to 
explain drug release mechanism in case of 
swelling along with gradual erosion of the matrix 
due to hydration [16,17]. Korsmeyer-Peppas 
equation is often used to describe drug release 
behaviour from polymeric systems when the 
mechanism is not well-known or when more than 
one type of release phenomena is involved. 
 
Statistical analysis  
 
In vitro drug release data were evaluated using 
GraphPad Prism 5 software and one-way 
ANOVA to determine differences among release 





Physical properties of matrix tablets 
 
Placebo tablets displayed flow and compression 
quality as “fair to passable” and “good” except a 
formulation containing 30 % XG (XG-30) showed 
poor characteristics (Table 2). However, addition 
of KT altered flowability and compressibility 
properties of powders with very poor flow and 
compression quality. “Poor” or “very poor” 
characteristics were observed with decrease in 
wax or polymer concentrations in general. In the 
case of bulk KT, the weakest CI and HR values 
were obtained. 
 
Tablet weights were between 176.7 ± 0.001 mg 
and 180.7 ± 0.001 mg for placebo tablets and, 
177.2 ± 0.001 mg and 182.8 ± 0.002 mg for KT 
tablets. The lowest tensile strength (0.37 Mpa) 
was obtained with KT tablets (Pr-30) based on 
Precirol at 30 % concentration. Friability values 
obtained were all below 0.5 %. Except for the 
tablet formulations PSA-30, PSA-40, SA-30 and 
SA-40, all the tablets did not disintegrate during 
10 h in the disintegration test performed in 
distilled water at 37 ± 0.5 oC. Formulations PSA-
30, PSA-40, SA-30 and SA-40 disintegrated after 
8, 7, 6 and 6 h, respectively. 
 
Table 2: Compression properties of powders and physical characterization of placebo and ketorolac tromethamol 
(KT) matrix tablets 
 
Formulation CI 
 (n = 10) 
Flow and 
compression quality 
  HR 
(n = 10) 
Weight ± SD 
(mg)  
(n = 20) 
Hardness 
(N)  
(n = 10) 
Tensile 










PCo-30 17.2 Fair to passable 1.20 179.5 ± 0.001 69.0 ± 1.47 1.49 
PCo-40 15.4 Good 1.18 179.9 ± 0.001 53.1 ± 1.67 1.10 
PPr-30 17.3 Fair to passable 1.21 180.7 ± 0.001 71.5 ± 2.45 1.48 
PPr-40 13.3 Good 1.15 177.9 ± 0.001 64.9 ± 2.55 1.38 
PSA-30 15.1 Good 1.18 179.6 ± 0.001 96.7 ± 1.47 2.04 
PSA-40 20.5 Fair to passable 1.26 179.2 ± 0.001 93.5 ± 1.28 1.94 
PHPMC-30 18.4 Fair to passable 1.23 176.7 ± 0.001 169.0 ± 9.22 3.86 
PHPMC-40 13.8 Good 1.16 180.2 ± 0.001 146.6 ± 0.10 3.37 
PXG-30 22.2 Poor 1.29 179.3 ± 0.001 117.3 ± 0.10 2.71 






Co-30  20.6  Fair to passable 1.26 178.9 ± 0.003 68.7 ± 4.51 1.44 
Co-40  25.5 Fair to passable 1.34 182.0 ± 0.002 68.8 ± 3.43 1.40 
Pr-30   28.4 Poor 1.40 182.2 ± 0.001 44.6 ± 3.73 0.86 
Pr-40   25.2 Fair to passable 1.34 177.2 ± 0.001 20.2 ± 2.84 0.37 
SA-30   30.8 Poor 1.45 179.1 ± 0.002 48.1 ± 20.59 0.92 
SA-40   33.0 Poor 1.49 179.0 ± 0.003 63.4 ± 22.85 1.31 
HPMC-30   19.3 Fair to passable 1.23 178.9 ± 0.001 61.7 ± 4.71 1.25 
HPMC-40   17.8 Fair to passable 1.22 182.8 ± 0.002 96.3 ± 10.00 1.98 
XG-30   32.0 Very poor 1.47 178.2 ± 0.001 66.5 ± 5.20 1.49 
XG-40   26.3 Poor 1.36 179.8 ± 0.002 33.4 ± 4.41 0.68 
Bulk KT  36.6 Very poor 1.58 - - - 
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Validation of spectrophotometric analysis    
 
The representative linear equation was A = aC + 
b, where C is the concentration, A the 
absorbance, a is the slope, and b is the intercept. 
In the current method, regression equations were 
A = 5.435C – 0.001 with r2 = 0.9998 in distilled 
water; A = 2.544C – 0.001 with r2 = 0.9972 in pH 
1.2 (HCl) solution; A = 5.485C – 0.001 with r2 = 
0.9999 in pH 7.2 (PB) solution. 
 
R.S.D. values obtained from intra-day and inter-
day precision of the analytical method were 
between 0.05 - 1.50 % in all media. Accuracy of 
the method was also expressed here as MRE; 
lower than 2 %, between 0 % and 1.67 %. 
Recovery of KT was between 97.25 and 100.00 
%. All other ingredients were found not to display 
absorbance at 323 nm which was maximum 
wavelength for KT in dissolution media indicating 
specificity of the method. It was demonstrated 
that they would not interfere quantification of KT 
by UV spectroscopy.   
 
Content uniformity of matrix tablets 
 
KT content of matrix tablets was between 38.85 
± 0.25 mg and 39.96 ± 0.08 mg. Thus, percent of 
KT content to the target content per dosage was 
between 97.125 % and 99.90 %. 
   
In vitro drug release from matrix tablets    
 
An insignificant difference was observed 
between KT release profiles of the matrix tablets 
prepared with HPMC (HPMC-30 and HPMC-40) 
and XG (XG-30 and XG-40) in water (p > 0.05). 
Those formulations displayed sustained drug 
release when matrix tablets prepared with waxes 
gave faster drug release (p < 0.05) (Fig. 1 and 
Table 3). On the other hand, the slowest drug 
release rates were obtained from matrix tablets 
in pH 1.2 among the other media (p < 0.05). 
Lower than 8 % of KT was released from 
formulations prepared with HPMC and XG at the 
12th hour (p > 0.05) when tablets prepared with 
Compritol, Precirol and SA displayed higher drug 
release between 11.72 and 20.93 % at pH 1.2 (p 
> 0.05). In the case of pH 7.2 (PB) solution, the 
slowest drug release profile was obtained from 
tablets prepared with HPMC at 40 % (HPMC-40) 
and XG at 30 % (XG-30) followed by 
formulations HPMC-30, XG-40, Co-30, Co-40, 
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Figure 1a-f: Release profiles of KT from matrix tablets in dissolution media – distilled water (a and b), pH 1.2 
(HCl) (c and d) and pH 7.2 (PB) (e and f) solutions; , −■ − = Co-30, −□− = Co-40, −▲− = Pr-30, −Δ− = Pr-40, 
−●− = SA-30, −○− = SA-40, ---- = HPMC-30, --■-- = HPMC-40, --▲-- = XG-30, --x-- = XG-40 
 
Table 3: Kinetic modelling of drug release from ketorolac tromethamol (KT) matrix tablets in distilled water, pH 
1.2 and pH 7.2, respectively 
 
Formulation Zero order  First order  Higuchi model  Exponential 
(Korsmeyer –  
Peppas model) 
Order of release 




(g/h) x 103 











































































































































































































































































































































r2: determination coefficient; K0: zero order release constant (mg%/h); K1: first order release constant (h-1); D: 
diffusion coefficient (mg%/h1/2); n: release exponent; n/a: not applicable 
 
Yener et al 




Content uniformity of KT tablets were in limits 
(85-115 % of target content), although powders 
of some formulations had poor flow and 
compression quality. Addition of KT herewith 
decrease in Avicel concentration may cause that. 
Because, Avicel presents acceptable flow 
properties required for succesful large-scale 
tableting [18]. The physical characteristics of the 
placebo and KT tablets met compendial 
requirements, indicating homogeneous blend of 
ingredients and sufficient powder characteristics 
during the large scale compression. Tensile 
strength and friability of the tablets lower than 0.5 
% indicated high mechanical strength of all the 
placebo and KT tablets. The satisfactory 
characteristics of the tablets can also be partially 
attributed to the addition of PVP-K 90, which 
displayed a good binding effect for formulations 
at 5 % concentration [18,19].  
 
Validation of a quantification method is the 
process used to confirm that the analytical 
procedure employed is suitable for its intended 
use [13]. Before starting to study on 
determination of content uniformity and drug 
release profiles of the matrix tablets, 
quantification method of KT by UV spectroscopy 
was validated in dissolution media. The 
validation process demonstrated that the results 
attained were fit for their intended purpose and 
performance verification of instrumentation and 
equipment is concerned with ensuring that they 
are performing correctly. 
 
Release profiles demonstrated a pH-dependent 
mechanism of KT release from matrix tablets 
(Fig. 1). Since ketorolac is a weak acid with a 
carboxylic acid group, the influence of an acid pH 
on solubility and dissolution is the main 
contributing factor. Solubility of KT were reported 
as 0.896, 0.315 and 0.886 mg/mL in distilled 
water, pH 1.2 (HCl) and pH 7.2 (PB) solutions, 
respectively [20]. Increase in pH resulted in an 
increase in KT release rates from all formulations  
 
As can be seen in this study , when a system 
composed of hydrophylic polymers like HPMC 
and XG gets in contact with aqueous medium, 
the medium difuses into the system [16,17,21]. 
Polymer at surface turns into a gel at first. When 
transfer of medium into the system continues, gel 
layer gets thicker and the system swells. In the 
meantime, outer gel layer continually 
regenerates. Drug release from KT matrix tablets 
fit the Higuchi kinetic model in general (Table 3). 
The release exponent of Korsmeyer-Peppas 
model (n) was taken into consideration as the 
parameter which is dependent on the release 
mechanism. Therefore, it was used to 
characterize drug release mechanism from 
matrix tablets. n ≤ 0.45 corresponds to the 
Fickian diffusion release (case I diffusion), 0.45 ≤ 
n < 0.89 to the non-Fickian (anomalous 
transport), n = 0.89 to the zero order release 
kinetics (case II), and n > 0.89 to the supercase 
II transport in case of cylindrical matrix tablets 
[16,17]. The mechanism of drug release up to 60 
% was Fickian (diffusion controlled release). The 
non-Fickian kinetics correspond to coupled 
diffusion/polymer relaxation that was clear with 
HPMC and XG tablets as could be expected.  
 
In the case of waxy tablets, differences were 
detected only up to the 4th h and then, tablets 
displayed the same profiles. More than 90 % of 
KT was released from tablets in distilled water 
and pH 7.2 (PB) solution at about the 6th h. The 
slowest release rate was observed with 
Compritol tablets followed by Precirol and SA. 
Release of KT from waxy tablets was also based 




An optimal formulation should be able to yield 
lower dose frequency and reduce dose-related 
side effects of drugs when administered orally. 
The matrix tablets of KT prepared with HPMC 
(30 or 40 %) displayed controlled drug release as 
well as the optimal compression properties 
required for large-scale production. However, 
further in vivo studies are required to 
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